Form 4: Lexaria Bioscience Corp. Director John Docherty Reports Stock Option Grant
SEC Form 4
John Docherty, a director and President of Lexaria Bioscience Corp., reports the acquisition of 49,500 stock options.
Summary
- On April 26, 2024, John Docherty, President and a director of Lexaria Bioscience Corp., reported a transaction involving derivative securities.
- Docherty acquired 49,500 stock options with an exercise price of $2.36, exercisable from April 26, 2024, and expiring on April 26, 2029.
- Following this transaction, Docherty directly owns 174,168 derivative securities in the form of stock options.
- Docherty also indirectly owns 54,075 common shares through a private holding company.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which can be seen as a positive sign of aligning management interests with shareholders, but doesn't inherently indicate strong positive or negative sentiment.
Positives
- The acquisition of stock options by a director and President may indicate confidence in the company's future performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives and directors.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment as it demonstrates the executive's belief in the company's future.
Key Dates
| Date | Description |
|---|---|
| 04/23/2020 | Date exercisable for 13,334 stock options at $3 |
| 04/23/2025 | Expiration date for 13,334 stock options at $3 |
| 04/26/2021 | Date exercisable for 18,000 stock options at $3 |
| 04/26/2026 | Expiration date for 18,000 stock options at $3 |
| 06/08/2021 | Date exercisable for 18,334 stock options at $3 |
| 06/08/2026 | Expiration date for 18,334 stock options at $3 |
| 09/01/2021 | Date exercisable for 15,000 stock options at $3 |
| 09/01/2026 | Expiration date for 15,000 stock options at $3 |
| 08/29/2022 | Date exercisable for 30,000 stock options at $2.91 |
| 08/29/2027 | Expiration date for 30,000 stock options at $2.91 |
| 05/09/2023 | Shareholder approval received for repricing of stock options |
| 10/26/2023 | Date exercisable for 30,000 stock options at $1.15 |
| 10/26/2028 | Expiration date for 30,000 stock options at $1.15 |
| 04/26/2024 | Date of transaction: John Docherty acquired 49,500 stock options at $2.36 |
| 04/26/2024 | Date exercisable for 49,500 stock options at $2.36 |
| 04/26/2029 | Expiration date for 49,500 stock options at $2.36 |
| 05/10/2024 | Date of signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.